But, with an ever-growing proportion of the cash going to a select few, the gulf between the haves and the have-nots is widening.
Life is returning to the IPO scene, but the recovery is slow and uncertain.
M&A moves are down, venture rounds few and IPOs nonexistent.
The group’s $270m series A, big for 2023, is not that impressive compared with other years.
The promise of fast timelines and early revenues lure a new investor into digital medicine.
But with only four IPOs so far this year, there is no disguising a moribund market.
Hopes for a better 2023 look optimistic as markets take another turn for the worse.
While venture investors keep the purse strings tight, they themselves continue to enjoy fundraising success.